Available Clinical Study Sites in the U.S.
The two-level prodisc C Vivo & prodisc C SK clinical study has expanded to multiple sites, each actively enrolling patients in the FDA monitored study. For more information, visit ClinicalTrials.gov (Identifier NCT04012996).
Arizona
Flagstaff, AZ
Investigator: John Hall, MD
California
Beverly Hills, CA
Investigators:
- Todd Lanman, MD
- Jason Cuellar, MD
Los Angeles, CA
Investigators:
- Brian Perri, MD
- Neel Anand, MD
- Patrick Hill, MD
- Edward Nomoto, MD
- Khawar Siddique, MD
- Albert Wong, MD
Los Angeles, CA
Investigator: Alexandre Rasouli, MD
Colorado
Thornton, CO
Investigator: Michael E. Janssen, DO
Florida
Sarasota, FL
Investigator: Ashvin Patel, MD
Temple Terrace, FL
Investigators:
- John Small, MD
- Adil Samad, MD
- Steven Tresser, MD
Indiana
Carmel, IN
Investigators:
- Rick Sasso, MD
- Paul Kraemer, MD
- Joseph Smucker, MD
Kentucky
Paducah, KY
Investigator: Kenneth Strenge, MD
Louisiana
Shreveport, LA
Investigators:
- Pierce Nunley, MD
- Peter Campbell, MD
- David Cavanaugh, MD
- Eubulus Kerr, MD
- Andrew Utter, MD
- Rishi Wadhwa, MD
Maryland
Baltimore, MD
Investigators:
- Daniel Gelb, MD
- Daniel Cavanaugh, MD
- Eugene Y Koh, MD
- Steven C Ludwig, MD
- Charlie Sansur, MD
Michigan
Royal Oak, MI
Investigators:
- Jad Khalil, MD
- Jeff Fischgrund, MD
- Mark Jacobson, MD
- Daniel Park, MD
Nevada
Las Vegas, NV
Investigator: Jason Garber, MD
New Jersey
Wayne, NJ
Investigators:
- Michael Faloon, MD
- Ki Soo Hwang, MD
- Kumar Sinha, MD
New York
New York, NY
Investigators:
- Aaron J. Buckland, MD
- John Bendo, MD
- Jeffrey Goldstein, MD
- Yong Kim, MD
- Themistocles Protopsaltis, MD
- Jeffrey Spivak, MD
North Carolina
Charlotte, NC
Investigators:
- Alden Milam, MD
- Bruce Darden, MD
- Eric Laxer, MD
- Leo Spector, MD
Durham, NC
Investigators:
- David Benjamin Musante, MD
- Matthew Hannibal, MD
Ohio
Solon, OH
Investigators:
- Robert McLain, MD
- James S Anderson, MD
Pennsylvania
Hershey, PA
Investigators:
- G. Timothy T. Reiter, MD
- John Paul Kelleher, MD
- Michael D. Sather, MD
Texas
Fort Worth, TX
Investigator: Jason Tinley, MD
Plano, TX
Investigators:
- Jessica Shellock, MD
- Scott Blumenthal, MD
- Richard Guyer, MD
- Michael Hisey, MD
- Jack Zigler, MD
Utah
Salt Lake City, UT
Investigator: Armen Khachatryan, MD
Washington, D.C.
Washington, D.C.
Investigator: Faheem Sandhu, MD
What should I expect?
What happens before the trial?
Before participating in a study, patients are provided with information about the study and are given the chance to ask questions. This process is called Informed Consent. The purpose of the informed consent process is to make sure patients are adequately informed of important details about the clinical study so they can make an informed choice about their participation. Informed Consent begins before a research volunteer agrees to participate in a trial and continues throughout the study.
The Informed Consent document describes the study to research patients. It includes details about the study’s purpose, length, procedures, risks and benefits, and other information that all patients should know. Patients sign the document before they enter the study, but only after having read and discussed it with the research team and demonstrating an understanding of the information provided. In some cases, there will be multiple Informed Consent documents throughout the study as changes are made to the study protocol or new safety information becomes available. Signing the document(s) and providing consent is not a contract. Patients may withdraw from a study at any time, even if the study is not over.
How am I protected during the trial?
The SMART Study has been reviewed and approved by the FDA. Hospitals and physicians won’t participate until their institutional review board (IRB) has thoroughly reviewed the study protocol and approved it. It is the responsibility of the IRB under federal guidelines to “protect the rights and welfare of research subjects.”
Your rights include:
- Ability to ask your physician or Centinel Spine about the study at any time.
- Privacy/confidentiality – your research records will be handled as confidentially as is possible within the law.
- Ability to withdraw your consent to participate in the study without penalty or loss of benefits at any time.
- Compensation for participation will be provided for your time. The ‘informed consent’ document outlines the details of this compensation.
- You will be informed of any new risks or findings during the course of the study.
What happens when the trial is over?
All anonymized patient data will be analyzed and submitted to the FDA for review. If the clinical trial is approved, the prodisc C SK and prodisc C Vivo can become available to other surgeons and patients in the U.S. Additionally, the results will be publicly shared on ClinicalTrials.gov, and in appropriate medical journals and with qualified medical professionals.
